Drug Sponsors

Mylan raises Perrigo offer, rejected again

Thursday, April 30, 2015 11:55 AM

Perrigo has rejected a revised, increased offer from global pharmaceutical company Mylan to acquire Perrigo, a global over-the-counter consumer goods and pharmaceutical company. Under the newest offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share.

More... »


Celgene to acquire Quanticel Pharmaceuticals for $100M in cash

Wednesday, April 29, 2015 12:14 PM

Celgene has announced a definitive share purchase agreement to acquire Quanticel Pharmaceuticals, a San Diego-based, privately held biotech company focused on cancer drug discovery.

More... »


Perrigo rejects Mylan’s second unsolicited offer

Monday, April 27, 2015 08:56 AM

Dublin-based Perrigo has rejected a second unsolicited offer from Mylan to acquire all outstanding shares of Perrigo for $60 per share in cash and 2.2 Mylan ordinary shares for each ordinary Perrigo share. Mylan is seeking to ward off an unsolicited offer from Israel-based Teva.  

More... »

Mylan to commence formal offer to acquire Perrigo

Friday, April 24, 2015 01:21 PM

On April 8, Mylan issued a Rule 2.4 announcement under the Irish Takeover Rules stating that it had made a non-binding proposal to acquire Perrigo for $205 in a combination of cash and Mylan stock for each Perrigo share. The Rule 2.4 announcement followed the delivery of that proposal to Perrigo's chairman on April 6.

More... »

Teva proposes to acquire Mylan for $82 per share in cash and stock

Wednesday, April 22, 2015 12:14 PM

Teva Pharmaceutical Industries has proposed to acquire all of the outstanding shares of Mylan in a transaction valued at $82 per Mylan share, with the consideration to be comprised of approximately 50% cash and 50% stock. The Teva cash and stock proposal provides Mylan stockholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger company.

More... »

Mylan comments on recent bid speculation

Tuesday, April 21, 2015 07:51 AM

Mylan executive chairman Robert J. Coury has commented on recent media speculation about a takeover bid from Teva.

More... »

Merck chairman, CEO Kenneth C. Frazier becomes PhRMA board chairman

Friday, April 17, 2015 12:40 PM

Kenneth C. Frazier, chairman and CEO of Merck, was elected chairman of the board of the Wash. D.C.-based Pharmaceutical Research and Manufacturers of America (PhRMA). At the board meeting, PhRMA’s president and CEO John J. Castellani announced he will be retiring Jan. 1, 2016. 

More... »

BioRestorative Therapies opens new headquarters, lab facility in New York

Wednesday, April 15, 2015 12:42 PM

BioRestorative Therapies (BRT), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, has relocated its corporate, administrative and laboratory operations to Melville, Long Island, N.Y.

More... »

Incyte to establish European headquarters in Geneva

Wednesday, April 15, 2015 12:41 PM

Incyte, a Wilmington, Del.-based biopharmaceutical company, will establish the new headquarters of Incyte Europe in Geneva, Switzerland. Incyte intends to use Incyte Europe as the base from which it will conduct its European clinical development operations, and expects to occupy the 9,000-square-foot facility by mid-2015.

More... »

Cipher Pharmaceuticals enters U.S. market with Innocutis acquisition

Monday, April 13, 2015 12:21 PM

Cipher Pharmaceuticals, a Canada-based specialty pharmaceutical dermatology company, has acquired Innocutis Holdings, a Charleston, S.C.-based, privately held specialty dermatology company, for $45.5 million in cash.

More... »

CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs